{
      "Rank": 715,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "Yes"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [
            "No"
      ],
      "ArmGroupDescription": [
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment."
      ],
      "ArmGroupInterventionName": [
            "Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.",
            "Other: Vehicle + Heparin along with best supportive care"
      ],
      "ArmGroupLabel": [
            "UC-MSCs Group",
            "Control Group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "<=18 years",
            "Between 18 and 65 years",
            ">=65 years",
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported",
            "Positive PRA",
            "Negative PRA",
            "Positive PRA",
            "Negative PRA",
            "Positive",
            "Negative",
            "Borderline",
            "Positive",
            "Negative",
            "Borderline"
      ],
      "BaselineClassDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "NCTId": [
            "NCT04355728"
      ],
      "BaselineClassDenomCountValue": [
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "11",
            "9",
            "20",
            "12",
            "12",
            "24",
            "11",
            "10",
            "21",
            "11",
            "10",
            "21",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "10",
            "10",
            "20",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "10",
            "10",
            "20",
            "10",
            "10",
            "20",
            "10",
            "11",
            "21",
            "10",
            "11",
            "21",
            "10",
            "10",
            "20",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "4",
            "6",
            "10",
            "4",
            "7",
            "11",
            "4",
            "4",
            "8",
            "12",
            "11",
            "23",
            "12",
            "12",
            "24",
            "12",
            "11",
            "23",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "8",
            "5",
            "13",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "12",
            "12",
            "24",
            "10",
            "9",
            "19",
            "10",
            "9",
            "19"
      ],
      "BaselineClassDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineClassTitle": [
            "United States",
            "PRA Results Class I",
            "PRA Results Class II",
            "IgM",
            "IgG"
      ],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineDenomCountValue": [
            "12",
            "12",
            "24"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineGroupTitle": [
            "UC-MSCs Group",
            "Control Group",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [
            "Alanine Aminotransferase (ALT) or serum glutamic-pyruvic transaminase (SGPT) for comprehensive metabolic panel as assessed from serum blood samples.",
            "Aspartate Aminotransferase (AST) or Serum Glutamic-Oxaloacetic Transaminase (SGOT) for the comprehensive metabolic panel assessed from serum blood samples.",
            "Measure of the fraction of inspired oxygen (FiO2) and its usage within the body during intensive care, measured using fNIRS (Functional Near Infrared Spectroscopy). The calculation for Oxygenation index is ((FIO2 * Mean airway pressure)/partial pressure of oxygen).",
            "Plateau pressure as assessed for patients on a ventilator",
            "Sequential Organ Failure Assessment (SOFA) Scores is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from a minimum of 0 (normal) to a maximum of 4 (high degree of dysfunction/failure). Totaling a maximum SOFA score of 24 and minimum of 0.",
            "D-dimer as assessed from serum blood samples.",
            "ratio of AA to EPA as assessed via serum blood samples.",
            "The ROX index is the measure of the ratio of pulse oximetry/fraction of inspired oxygen (SpO2/FiO2) to respiratory rate (RR). The ROX index is used as a predictor of the need to intubate in patients receiving HFNC oxygen therapy; performed at 2, 6 and 12 hours. ROX at 2, 6 and 12 hours after HFNC initiation was associated with a lower risk for intubation. For a ROX Index <3.85, risk of HFNC failure is high. If ROX Index 3.85 to <4.88, the scoring could be repeated one or two hours later for further evaluation.",
            "Viral load as assessed in blood plasma for SARS-CoV-2",
            "Panel Reactive Antibody (PRA) for Class I and Class II assessed via serum blood samples",
            "Serology (anti-SARS-CoV-2 IgM and IgG) analyzed in blood serum samples."
      ],
      "BaselineMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Inter-Quartile Range"
      ],
      "BaselineMeasureParamType": [
            "Count of Participants",
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Number",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Median",
            "Count of Participants",
            "Count of Participants"
      ],
      "BaselineMeasurePopulationDescription": [
            "Data missing. CBC with differential at baseline was not done in a subset of patients.",
            "Data missing. CBC with differential at baseline was not done in a subset of patients.",
            "Data missing. CBC with differential at baseline was not done in a subset of patients.",
            "Data missing. Comprehensive metabolic panel was not completed (only basal metabolic panel) in some patients.",
            "Data missing. Comprehensive metabolic panel was not completed (only basal metabolic panel) in some patients.",
            "Data missing. Comprehensive metabolic panel was not completed (only basal metabolic panel) in some patients.",
            "Data missing. Comprehensive metabolic panel was not completed (only basal metabolic panel) in some patients.",
            "Data missing. Comprehensive metabolic panel was not completed (only basal metabolic panel) in some patients.",
            "Data missing. Comprehensive metabolic panel was not completed (only basal metabolic panel) in some patients.",
            "Data missing. Oxidation Index is only measured and calculated in ventilated patients.",
            "Data missing. PEEP is only measured in patients on ventilator.",
            "Data missing. Plateau Pressure is only measured in patients on ventilator.",
            "Data missing.",
            "data missing. Collected in a tube that has been recalled by the manufacturer so test was canceled by Quest",
            "data missing. Some patients were on a ventilator. Patients only on HFNC have ROX scores.",
            "These analyses were implemented in a protocol version that did not apply to two patients of the UC-MSC treatment group and three patients of the control group."
      ],
      "BaselineMeasureTitle": [
            "Age, Categorical",
            "Age, Continuous",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)",
            "Region of Enrollment",
            "Hemogoblin from Complete Blood Count",
            "Hematocrit from Complete Blood Count",
            "White Blood Count (WBC) from Complete Blood Count",
            "Neutrophils from Complete Blood Count",
            "Lymphocytes from Complete Blood Count",
            "Platelet count from Complete Blood Count",
            "Glomerular Filtration Rate from Comprehensive Metabolic Panel",
            "Total Protein from Comprehensive Metabolic Panel",
            "Sodium for Comprehensive Metabolic Panel",
            "Potassium for Comprehensive Metabolic Panel",
            "Creatine for Comprehensive Metabolic Panel",
            "Glucose for Comprehensive Metabolic Panel",
            "Albumin for Comprehensive Metabolic Panel",
            "Alkaline Phosphatase for Comprehensive Metabolic Panel",
            "Alanine Aminotransferase (ALT) or Serum Glutamic-pyruvic Transaminase (SGPT)",
            "Aspartate Aminotransferase (AST) or Serum Glutamic-Oxaloacetic Transaminase (SGOT)",
            "Total Bilirubin for Comprehensive Metabolic Panel",
            "Blood Urea Nitrogen (BUN) for Comprehensive Metabolic Panel",
            "Calcium for Comprehensive Metabolic Panel",
            "Chloride Comprehensive Metabolic Panel",
            "Carbon Dioxide (CO2) for Comprehensive Metabolic Panel",
            "Oxygenation Index",
            "Positive End-Expiratory Pressure (PEEP)",
            "Plateau Pressure",
            "Sequential Organ Failure Assessment (SOFA) Score",
            "C-Reactive Protein (CRP)",
            "D-Dimer",
            "Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio",
            "25-OH vitamin D levels",
            "Respiratory Rate and Oxygenation Index (ROX)",
            "Viral Load by SARS-CoV-2 RT-PCR",
            "Panel Reactive Antibody (PRA)",
            "Serology (anti-SARS-CoV-2 IgM and IgG)"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "Participants",
            "years",
            "Participants",
            "Participants",
            "Participants",
            "participants",
            "g/dL",
            "percentage of total blood volume",
            "10^3 cells/uL",
            "10^3 cells/uL",
            "10^3 cells/uL",
            "10^3 cells/uL",
            "mL/min/1.73 m^2",
            "g/dL",
            "mmol/L",
            "mmol/L",
            "mg/dL",
            "mg/dL",
            "g/dL",
            "U/L",
            "U/L",
            "U/L",
            "mg/dL",
            "mg/dL",
            "mg/dL",
            "mmol/L",
            "mmol/L",
            "Index",
            "cm H2O",
            "cm H2O",
            "score on a scale",
            "mg/L",
            "mcg/mL FEU",
            "ratio of AA to EPA",
            "ng/ml",
            "Index",
            "copies",
            "Participants",
            "Participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineMeasurementLowerLimit": [
            "47",
            "175",
            "114"
      ],
      "BaselineMeasurementSpread": [
            "15.93",
            "11.61",
            "13.63",
            "2.04",
            "2.35",
            "2.17",
            "6.53",
            "5.08",
            "5.79",
            "5.26",
            "5.45",
            "5.37",
            "4.8",
            "5.33",
            "5.36",
            "0.79",
            "0.25",
            "0.62",
            "99.52",
            "91.83",
            "93.88",
            "31.61",
            "37.59",
            "34.63",
            "0.69",
            "0.68",
            "0.67",
            "3.15",
            "5.04",
            "4.28",
            "0.55",
            "0.67",
            "0.6",
            "0.77",
            "1.88",
            "1.46",
            "107.14",
            "85.44",
            "94.78",
            "0.39",
            "0.51",
            "0.44",
            "59.3",
            "52.69",
            "54.67",
            "51.19",
            "75.18",
            "63.51",
            "31.07",
            "153.16",
            "114.86",
            "0.39",
            "0.25",
            "0.32",
            "16.61",
            "31.27",
            "25.38",
            "0.4",
            "0.87",
            "0.67",
            "4.29",
            "6.33",
            "5.29",
            "3.99",
            "4.62",
            "4.41",
            "2.63",
            "14.68",
            "11.5",
            "2.06",
            "2.14",
            "2.07",
            "9.74",
            "7.39",
            "11.43",
            "2.61",
            "3.35",
            "3.12",
            "77.56",
            "115.69",
            "99.19",
            "2.35",
            "6.04",
            "4.69",
            "24.89",
            "23.93",
            "23.88",
            "8.48",
            "12.85",
            "10.68",
            "7.73",
            "1.13",
            "6.24"
      ],
      "BaselineMeasurementUpperLimit": [
            "2184.5",
            "18408.50",
            "10799.50"
      ],
      "BaselineMeasurementValue": [
            "0",
            "0",
            "0",
            "8",
            "7",
            "15",
            "4",
            "5",
            "9",
            "58.58",
            "58.83",
            "58.71",
            "7",
            "4",
            "11",
            "5",
            "8",
            "13",
            "11",
            "11",
            "22",
            "1",
            "1",
            "2",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "2",
            "3",
            "11",
            "10",
            "21",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "12",
            "12",
            "24",
            "12.93",
            "12.45",
            "12.69",
            "39.71",
            "40.76",
            "40.18",
            "11.87",
            "14.17",
            "13.02",
            "9.25",
            "13.37",
            "11.21",
            "1.15",
            "0.72",
            "0.95",
            "329.83",
            "342.58",
            "336.21",
            "74.5",
            "61.25",
            "67.88",
            "6.39",
            "6.45",
            "6.42",
            "138.92",
            "136.58",
            "137.75",
            "4.37",
            "4.52",
            "4.44",
            "1.18",
            "1.92",
            "1.55",
            "190.75",
            "193.67",
            "192.21",
            "3.22",
            "3.21",
            "3.22",
            "90.9",
            "96.5",
            "93.7",
            "72.1",
            "82.45",
            "77.52",
            "55.8",
            "118.45",
            "88.62",
            "0.62",
            "0.65",
            "0.64",
            "29.58",
            "42.67",
            "36.13",
            "8.53",
            "8.32",
            "8.43",
            "101",
            "100.5",
            "100.75",
            "24.42",
            "21.92",
            "23.17",
            "8.09",
            "14.32",
            "11.83",
            "13.75",
            "12.71",
            "13.09",
            "13.75",
            "29",
            "21.38",
            "5.5",
            "7.64",
            "6.52",
            "97.97",
            "144.35",
            "121.16",
            "1.76",
            "4.96",
            "3.29",
            "45.38",
            "45.79",
            "45.58",
            "21.76",
            "23.19",
            "22.47",
            "7.36",
            "3.59",
            "5.91",
            "352",
            "3570.50",
            "710",
            "11",
            "9",
            "20",
            "1",
            "3",
            "4",
            "4",
            "6",
            "10",
            "8",
            "6",
            "14",
            "4",
            "5",
            "9",
            "6",
            "2",
            "8",
            "0",
            "2",
            "2",
            "5",
            "8",
            "13",
            "4",
            "1",
            "5",
            "1",
            "0",
            "1"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)."
      ],
      "BriefTitle": [
            "Use of UC-MSCs for COVID-19 Patients"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "October 31, 2020"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Corona Virus Infection",
            "ARDS",
            "ARDS, Human",
            "Acute Respiratory Distress Syndrome",
            "COVID-19"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000012141",
            "D000007239",
            "D000011024",
            "D000011014",
            "D000014777",
            "D000003333",
            "D000030341",
            "D000012327",
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Respiratory Tract Infections",
            "Infections",
            "Pneumonia, Viral",
            "Pneumonia",
            "Virus Diseases",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC08",
            "All",
            "BC23",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "COVID-19",
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Corona Virus Infection",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M2562",
            "M15507",
            "M14117",
            "M9435",
            "M5520",
            "M16674",
            "M14116",
            "M27297",
            "M19643",
            "M27296",
            "M14130",
            "M13056",
            "M13066",
            "M5707",
            "M22838",
            "M14301",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "COVID-19",
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Infections",
            "Communicable Diseases",
            "Virus Diseases",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Coronavirus Infections",
            "Lung Injury",
            "Respiratory Tract Infections",
            "Pneumonia",
            "Pneumonia, Viral",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000086382",
            "D000018352",
            "D000012128",
            "D000012127",
            "D000055371",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "COVID-19",
            "Coronavirus Infections",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "The trial has two groups, each with 12 subjects (n=24). All eligible subjects will be randomized to either the treatment group or standard of care, and randomization will be stratified by ARDS severity."
      ],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [
            "Double-Blinding Trial"
      ],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients >/= 18 years old diagnosed with COVID-19 (as evaluated by PCR test confirming infection with SARS-CoV-2) will be eligible for inclusion if they meet all of the below criteria. Inclusion criteria must all be present within a 24-hour time period at the time of enrollment:\n\nPatient currently hospitalized\nAged \u2265 18 years\nWilling and able to provide written informed consent, or with a legal representative who can provide informed consent\nPeripheral capillary oxygen saturation (SpO2) \u2264 94% at room air, or requiring supplemental oxygen at screening\nPaO2/FiO2 ratio < 300 mmHg\nBilateral infiltrates on frontal chest radiograph or bilateral ground glass opacities on a chest CT scan\nHypoxemia requiring an increase in the fraction of inspired oxygen (FiO2) of \u2265 20% AND an increase in positive end-expiratory airway pressure (PEEP) level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%, or requirement for escalation from oxygen therapy to invasive mechanical ventilation\n\nExclusion Criteria:\n\nPaO2/FiO2 \u2265 300 at the time of enrollment\nA previous MSC infusion not related to this trial\nHistory of Pulmonary Hypertension (WHO Class III/IV)\nHistory of left atrial hypertension or decompensated left heart failure.\nPregnant or lactating patient\nUnstable arrhythmia\nPatients with previous lung transplant\nPatients currently receiving chronic dialysis\nPatients currently receiving Extracorporeal Membrane Oxygenation (ECMO)\nPresence of any active malignancy (except non-melanoma skin cancer)\nAny other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%\nModerate to severe liver disease (AST and ALT >5 X ULN)\nSevere chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen\nBaseline QT prolongation\nMoribund patient not expected to survive > 24 hours"
      ],
      "EnrollmentCount": [
            "24"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "3",
            "7"
      ],
      "EventGroupDeathsNumAtRisk": [
            "12",
            "12"
      ],
      "EventGroupDescription": [
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol."
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "8",
            "10"
      ],
      "EventGroupOtherNumAtRisk": [
            "12",
            "12"
      ],
      "EventGroupSeriousNumAffected": [
            "5",
            "8"
      ],
      "EventGroupSeriousNumAtRisk": [
            "12",
            "12"
      ],
      "EventGroupTitle": [
            "UC-MSCs Group",
            "Control Group"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "3 months"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "12",
            "12",
            "12",
            "12",
            "0",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol."
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "UC-MSCs Group",
            "Control Group"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000925",
            "D000005343",
            "D000050299",
            "D000045504"
      ],
      "InterventionAncestorTerm": [
            "Anticoagulants",
            "Fibrinolytic Agents",
            "Fibrin Modulating Agents",
            "Molecular Mechanisms of Pharmacological Action"
      ],
      "InterventionArmGroupLabel": [
            "UC-MSCs Group",
            "Control Group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "FiAg",
            "AnCoag",
            "All",
            "BDCA"
      ],
      "InterventionBrowseBranchName": [
            "Fibrinolytic Agents",
            "Anticoagulants",
            "All Drugs and Chemicals",
            "Bone Density Conservation Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Who are",
            "Who are"
      ],
      "InterventionBrowseLeafId": [
            "M8731",
            "M45326",
            "M3396",
            "M4533",
            "M4550",
            "M7625"
      ],
      "InterventionBrowseLeafName": [
            "Heparin",
            "Calcium heparin",
            "Anticoagulants",
            "Calcium",
            "Calcium, Dietary",
            "Fibrinolytic Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Best supportive care treatment per the treating hospital protocol."
      ],
      "InterventionMeshId": [
            "D000006493",
            "C000006871"
      ],
      "InterventionMeshTerm": [
            "Heparin",
            "Calcium heparin"
      ],
      "InterventionName": [
            "Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.",
            "Vehicle + Heparin along with best supportive care"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "COVID-19"
      ],
      "LargeDocDate": [
            "February 12, 2021"
      ],
      "LargeDocFilename": [
            "Prot_SAP_000.pdf"
      ],
      "LargeDocHasICF": [
            "No"
      ],
      "LargeDocHasProtocol": [
            "Yes"
      ],
      "LargeDocHasSAP": [
            "Yes"
      ],
      "LargeDocLabel": [
            "Study Protocol and Statistical Analysis Plan"
      ],
      "LargeDocTypeAbbrev": [
            "Prot_SAP"
      ],
      "LargeDocUploadDate": [
            "10/14/2021 11:23"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "December 6, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "December 1, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Camillo Ricordi"
      ],
      "LimitationsAndCaveatsDescription": [
            "The inferences we make from the efficacy results observed in this phase 1/2a trial in 24 subjects, including the outcome of survival, are still subject to limitations of sample size and potential bias because of factors we were not yet aware of."
      ],
      "LocationCity": [
            "Miami"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "Diabetes Research Institute, University of Miami Miller School of Medicine"
      ],
      "LocationState": [
            "Florida"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "33136"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Miami"
      ],
      "OrgStudyId": [
            "20200671"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "Cardiac disorders",
            "Cardiac disorders",
            "Infections and infestations",
            "Cardiac disorders",
            "Cardiac disorders",
            "Endocrine disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Hepatobiliary disorders",
            "Hepatobiliary disorders",
            "Hepatobiliary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Vascular disorders",
            "Infections and infestations",
            "General disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Musculoskeletal and connective tissue disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders"
      ],
      "OtherEventSourceVocabulary": [
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0"
      ],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "0",
            "1",
            "1",
            "1",
            "1",
            "0",
            "2",
            "0",
            "0",
            "1",
            "0",
            "2",
            "0",
            "1",
            "1",
            "0",
            "0",
            "2",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "2",
            "3",
            "3",
            "0",
            "1",
            "2",
            "0",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "3",
            "2",
            "2",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "1",
            "2",
            "5",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "2",
            "0",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "0",
            "1",
            "4",
            "0"
      ],
      "OtherEventStatsNumAtRisk": [
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12"
      ],
      "OtherEventStatsNumEvents": [
            "0",
            "1",
            "1",
            "1",
            "1",
            "0",
            "2",
            "0",
            "0",
            "1",
            "0",
            "2",
            "0",
            "1",
            "1",
            "0",
            "0",
            "3",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "2",
            "3",
            "3",
            "0",
            "1",
            "2",
            "0",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "3",
            "2",
            "2",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "1",
            "2",
            "5",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "2",
            "0",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "0",
            "1",
            "4",
            "0"
      ],
      "OtherEventTerm": [
            "Atrial Fibrillation",
            "Bradycardia",
            "Exacerbation of COVID ARDS-Septic Shock",
            "Tachycardia",
            "Tachycardia after infusion of Investigational Product",
            "Hyperglycemia",
            "Clostridium Difficile Infection",
            "Mild Gastrointestinal Bleeding",
            "Transaminitis/Transaminitis-Liver Shock",
            "Increased ALT, AST, and Alkaline Phosphatase",
            "Increased Direct Bilirubin",
            "Abnormal Urinalysis",
            "Candiduria",
            "Anemia",
            "Leukocytosis/Leukocytosis (Increased WBC)",
            "Severe Thrombocytopenia",
            "Thrombocytopenia/Heparin-induced Thrombocytopenia",
            "Thrombocytosis",
            "Bilateral Common Femoral Vein DVT",
            "Candida Albicans Fungemia",
            "Fever",
            "Hypernatremia",
            "Mild Hyponatremia",
            "Hypokalemia",
            "Hyperkalemia",
            "MRSA Bacteremia",
            "Paenebacillus Pabuli Bacteremia",
            "Positive Blood Culture Streptococcus Mitis and Streptococcus Oralis",
            "Staphylococcus haemolyticus bacteremia and Candida orthopsilosi Fungemia",
            "Staphylococcus Hominis Bacteremia/Staphylococcus Bacteremia",
            "Left Calf Collection",
            "Encephalopathy",
            "Dysconjugated gaze",
            "Urinary Tract Infection",
            "Acute Kidney Injury/Oliguric Acute Kidney Injury/ Anuric Acute Kidney Injury/Acute Kidney Injury (AK",
            "Pneumoperitoneum",
            "Aspiration Pneumonitis, suspected",
            "Bradypnea",
            "Enterococcus Faecalis, Klebsiella Pneumoniae, Candida Auris/Duobushaemulonis in bronchial aspirate",
            "Enterococcus Pneumonia",
            "MRSA Hospital Acquired Pneumonia",
            "Pneumomediastinum",
            "Respiratory Failure - Intubation/Hypoxemic respiratory failure requiring intubation and mechanical v",
            "Subcutaneous Emphysema",
            "Ventilator Acquired Pneumonia (VAP) with Pseudomona aureginosa",
            "Worsening of Hypoxemia/Deterioration of Hypoxia"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [
            "0.088",
            "-6404.7"
      ],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [
            "2-Sided",
            "2-Sided"
      ],
      "OutcomeAnalysisCIPctValue": [
            "95",
            "95"
      ],
      "OutcomeAnalysisCIUpperLimit": [
            "0.948",
            "-591.2"
      ],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [
            "Standard Deviation"
      ],
      "OutcomeAnalysisDispersionValue": [
            "3078.2"
      ],
      "OutcomeAnalysisEstimateComment": [
            "Censoring was limited to dropout from study, and the event of interest was recovery. In the case of death, the patient's time to recovery was censored at the end of study observation; thus the patient remained in the risk set for all KM estimations."
      ],
      "OutcomeAnalysisGroupDescription": [
            "The null hypothesis is the following: \"There is no difference in the number of subjects experiencing serious adverse events in the UC-MSC vs control group\".",
            "The null hypothesis is the following: \"There is no difference in Time to Recovery up to 31 days post infusion between the UC-MSC group and control group\". Time to recovery was estimated in each group with Kaplan-Meier survival estimates. Log-rank tests were used to compare hazards between groups.",
            "Null Hypothesis: The center of the distributions of ventilator free days are equal in the UC-MSC and control group.",
            "Null Hypothesis: The center of the distributions of ventilator free days are equal in the UC-MSC and control group.",
            "The null hypothesis is the following: \"There is no association between PRA (class I) status and treatment group at 3 days post first infusion\".",
            "The null hypothesis is the following: \"There is no association between PRA (class II) status and treatment group at 3 days post first infusion.\"",
            "The null hypothesis is the following: \"There is no association between PRA (class I) status and treatment group at 6 days post first infusion\".",
            "The null hypothesis is the following: \"There is no association between PRA (Class II) status and treatment group at 6 days post first infusion\".",
            "The null hypothesis is the following: \"There is no association between PRA (class I) status and treatment group at 14 days post first infusion\".",
            "The null hypothesis is the following: \"There is no association between PRA (class II) status and treatment group at 14 days post first infusion\"."
      ],
      "OutcomeAnalysisGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority",
            "Superiority"
      ],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [
            ".04",
            "0.0307",
            ".0563",
            ".0563",
            "0.0356",
            "0.0215",
            "0.0210",
            "0.48",
            "0.41",
            "1.00",
            "1.00",
            "0.44",
            "0.5238"
      ],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [
            "Hazard Ratio (HR)",
            "Mean Difference (Net)"
      ],
      "OutcomeAnalysisParamValue": [
            "0.289",
            "-3498"
      ],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [
            "Fisher Exact",
            "Log Rank",
            "Wilcoxon (Mann-Whitney)",
            "Wilcoxon (Mann-Whitney)",
            "Wilcoxon (Mann-Whitney)",
            "Wilcoxon (Mann-Whitney)",
            "t-test, 2 sided",
            "Fisher Exact",
            "Fisher Exact",
            "Fisher Exact",
            "Fisher Exact",
            "Fisher Exact",
            "Fisher Exact"
      ],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [
            "PRA Positive",
            "PRA Negative",
            "PRA Positive",
            "PRA Negative",
            "PRA Positive",
            "PRA Negative",
            "PRA Positive",
            "PRA Negative",
            "PRA Positive",
            "PRA Negative",
            "PRA Positive",
            "PRA Negative",
            "Positive",
            "Negative",
            "Borderline",
            "Positive",
            "Negative",
            "Borderline"
      ],
      "OutcomeClassDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeClassDenomCountValue": [
            "12",
            "12",
            "4",
            "7",
            "8",
            "5",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "3",
            "3",
            "3",
            "2"
      ],
      "OutcomeClassDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeClassTitle": [
            "Number of subjects with an increase in vasopressor dose at 6 h",
            "In subjects receiving mechanical ventilation, Number of subjects with worsening of hypoxemia at 6 h",
            "In subjects on high flow oxygen therapy:worsening hypoxemia(req intubat, mechanical ventilat) at 6 h",
            "Number of subjects with new cardiac arrhythmia requiring cardioversion at 6 h",
            "Number of subjects with new ventricular tachycardia, ventricular fibrillation, or asystole at 6 h",
            "A clinical scenario consistent with transfusion incompatibility or transfusion-rel infection at 6h",
            "Number of subjects with cardiac arrest or death within 24 h post infusion",
            "Number of Adverse Events (not including SAEs)",
            "Number of Serious Adverse Events",
            "Mild",
            "Moderate",
            "Severe",
            "Mild",
            "Moderate",
            "Severe",
            "Unrelated",
            "Unlikely",
            "Possible",
            "Probably",
            "Definite",
            "Unrelated",
            "Unlikely",
            "Possible",
            "Probable",
            "Defininte",
            "Days by which 75% of subjects were recovered",
            "Days by which 50% of subjects were recovered",
            "Days by which 25% of subjects were recovered",
            "PEEP",
            "Plateau Pressure",
            "Class I",
            "Class II",
            "Class I",
            "Class II",
            "Class I",
            "Class II",
            "IgM",
            "IgG"
      ],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "11",
            "12",
            "11",
            "12",
            "12",
            "12",
            "10",
            "11",
            "10",
            "11",
            "5",
            "7",
            "3",
            "3",
            "3",
            "3",
            "9",
            "11",
            "0",
            "0",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "8",
            "9",
            "8",
            "9",
            "9",
            "9",
            "5",
            "6",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "5",
            "6",
            "5",
            "6",
            "5",
            "6",
            "5",
            "6",
            "5",
            "6",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "9",
            "8",
            "11",
            "10",
            "11",
            "9",
            "10",
            "10",
            "11",
            "11",
            "11",
            "11",
            "11",
            "11",
            "9",
            "10",
            "11",
            "12",
            "11",
            "10",
            "11",
            "5",
            "4",
            "4",
            "2"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
            "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
            "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol."
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group",
            "UC-MSCs Group",
            "Control Group"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Safety as defined by the number of pre-specified infusion associated adverse events as assessed by treating physician. Any of the following occurring within 6 h post each infusion:\n\nAn increase in vasopressor dose greater than or equal to the following:\n\nNorepinephrine: 10 \u03bcg/min\nPhenylephrine: 100 \u03bcg/min\nDopamine: 10 \u03bcg/kg/min\nEpinephrine: 10 \u03bcg/min\nIn patients receiving mechanical ventilation: worsening hypoxemia, as assessed by a requirement for an increase of PEEP by 5 cm H2O over baseline, or requirement to increase FiO2 of >20%.\nIn patients receiving high flow oxygen therapy: worsening hypoxemia, as indicated by requirement of intubation and mechanical ventilation.\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fibrillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24h post infusion",
            "The number of subjects experiencing serious adverse events by 31 days after the first infusion (corresponding to 28 days after the last infusion).",
            "Safety will be reported as the percentage of participants experiencing serious adverse events through Day 90 as assessed by treating physician.",
            "Total number of adverse events and serious adverse events as assessed by treating physician",
            "Total number of adverse events plus serious adverse events categorized by severity.",
            "Total number of subjects with adverse events and serious adverse events categorized by severity.",
            "Total number of adverse events and serious adverse events categorized by relatedness to treatment defined by a medical professional.",
            "Total number of subjects with adverse events categorized by relatedness to treatment by a medical professional",
            "Number of participants that are alive at 31 days post first infusion follow up corresponding to 28 day post second infusion.",
            "Number of participants alive at 60 days post first infusion follow up.",
            "Time to discharge or, if the subject was hospitalized, no longer requiring supplemental oxygen and no longer requiring COVID-19-related medical care by 31 days. The numbers represent days at which 25%, 50%, 75% subjects within the treatment group had recovered.",
            "Number of days participants were off ventilators during 28 days post second infusion.",
            "Number of days participants were off ventilators within up to 90 days of hospitalization.",
            "Respiratory Rate-Oxygenation (ROX) index is defined as the ratio of oxygen saturation as measured by pulse oximetry (SpO2)/ Fraction of inspired oxygen (FiO2) to respiratory rate. This index can be used in the assessment of disease progression and the risk of intubation in COVID-19 patients with pneumonia.",
            "Measure of the fraction of inspired oxygen (FiO2) and its usage within the body during intensive care, measured using fNIRS (Functional Near Infrared Spectroscopy). The calculation for Oxygenation index is ((FIO2 * Mean airway pressure)/partial pressure of oxygen).",
            "Measuring the respiratory mechanics; positive end-expiratory pressure (PEEP) and plateau pressure (Pplat) in ventilated patients visit 8 (day 6)",
            "Sequential Organ Failure Assessment (SOFA) Scores is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from a minimum of 0 (normal) to a maximum of 4 (high degree of dysfunction/failure). The total score corresponds to the sum of the six different scores of the organ systems. In total, the minimum SOFA score is 0 (normal) and the maximum SOFA score is 24 (highest degree dysfunction/failure).",
            "SIT measures the participant's sense of smell. SIT has a total score ranging from 0 to 40 with the higher the score indicating a more normal sense of smell",
            "As assessed via serum blood samples.",
            "As assessed via serum blood samples.",
            "Measures the total amount of the oxygen-carrying protein in the blood as assessed via serum blood samples.",
            "The percentage by volume of red cells in your blood as assessed via serum blood samples.",
            "the amount of immune cells (that is one of the first cell types to travel to the site of an infection) as assessed via serum blood samples",
            "Lymphocyte count as assessed via serum blood samples",
            "Glomerular filtration rate (GFR) as assessed via serum blood samples to check how well the kidneys are working. It estimates how much blood passes through the glomeruli each minute.",
            "Total protein as assessed via serum blood samples as a part of the comprehensive metabolic panel (CMP). It is a measurement of the sum of albumin and globulins.",
            "Sodium levels as assessed by serum blood samples.",
            "Potassium levels as assessed via serum blood samples.",
            "Creatinine levels as assessed via serum blood samples",
            "Glucose levels as assessed via serum blood samples",
            "Albumin levels as assessed via serum blood samples",
            "Alkaline phosphatase levels as assessed via serum blood samples for the Comprehensive Metabolic Panel.",
            "The alanine aminotransferase or serum glutamate-pyruvate transaminase (ALT or SGPT) test as assessed via serum blood samples",
            "The aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST or SGOT) test as assessed via serum blood samples",
            "Bilirubin levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Blood urea nitrogen (BUN) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Calcium levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Chloride levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Carbon Dioxide (CO2) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "As assessed via serum blood samples.",
            "As assessed via serum blood samples on day 6 (visit 8).",
            "As assessed via serum blood samples.",
            "As assessed via serum blood samples.",
            "Analysis of TNF\u03b1 in peripheral blood plasma",
            "Analysis of TNF\u03b2 in peripheral blood plasma",
            "Analysis of soluble tumor necrosis factor receptor 2 (sTNFR2) in peripheral blood plasma",
            "Viral load as assessed in blood plasma for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) via Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).",
            "Number of participants reporting panel reactive antibody (PRA) positivity at Day 3 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
            "Number of participants reporting panel reactive antibody (PRA) positivity at Day 6 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
            "Number of participants reporting panel reactive antibody (PRA) positivity at Day 14 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
            "Number of participants with positive, negative, or borderline SARS-CoV-2 Immunoglobulin M (IgM)/Immunoglobulin G (IgG) serology from serum blood samples."
      ],
      "OutcomeMeasureDispersionType": [
            "95% Confidence Interval",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Standard Deviation",
            "Inter-Quartile Range"
      ],
      "OutcomeMeasureParamType": [
            "Count of Participants",
            "Count of Participants",
            "Number",
            "Number",
            "Number",
            "Count of Participants",
            "Number",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Number",
            "Median",
            "Median",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Median",
            "Median",
            "Mean",
            "Median",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants"
      ],
      "OutcomeMeasurePopulationDescription": [
            "In the UC-MSC treatment group, 4 participants were on mechanical ventilation and 8 participants were receiving high flow oxygen therapy. In the control group 7 participants were on mechanical ventilation and 5 participants were receiving high flow oxygen therapy.",
            "Subjects who experience one or more AEs or SAEs within each category are counted only once.",
            "One subject in the UC-MSC Group was not included in the data analysis due to failed intubation.",
            "A subject was censored due to failed intubation in the UC-MSC group.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to censoring and another subject was not included due to loss to follow-up. In the control group one subject was not included in the analysis due to discharge against medical advice.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to censoring and another subject was not included due to loss to follow-up. In the control group one subject was not included in the analysis due to discharge against medical advice.",
            "ROX index was only measured for patients receiving HFNC and/or not intubated patients. Three patients were ventilated in the UC-MSC group, one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, two patients data was not collected. In the control group one subject was not included in the analysis due to death before day 6, three patients were ventilated, and one patient data was not collected.",
            "Oxidation Index is only measured and calculated in ventilated patients, therefore 3 patients in the UC-MSC group were included and 3 patients in the control group were included.",
            "PEEP and Plateau pressure are only measured in ventilated patients, therefore 3 patients in the UC-MSC group were included and 3 patients in the control group were included.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to death and 2 subjects were not included due to discharge on day 6. In the control group one subject was not included in the analysis due to death before day 6.",
            "No participants in the study were able to complete the Smell Evaluation Test due to extenuating circumstances related to the COVID-19 pandemic.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and two subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and two subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and 5 subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, and 5 subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and 5 subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, and 5 subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and 5 subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, and 5 subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and 5 subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, and 5 subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and 5 subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, and 5 subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and 5 subjects data was not collected. In the control group one subject was not included in the analysis due to death before day 6, and 5 subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6, two subjects data was not collected.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and data was missing for two subjects. In the control group one subject was not included in the analysis due to death before day 6.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6. In the control group one subject was not included in the analysis due to death before day 6.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6, and one subject data was not collected. In the control group one subject was not included in the analysis due to death before day 6 and one subject data was not collected.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6. In the control group one subject was not included in the analysis due to death before day 6.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to failed intubation. In the control group one subject was not included in the analysis because of death before day 6 blood draw.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to failed intubation. In the control group one subject was not included in the analysis because of death before day 6 blood draw.",
            "In the UC-MSC treatment group one subject was not included in the analysis due to failed intubation. In the control group one subject was not included in the analysis because of death before day 6 blood draw and data was unavailable for two patients.",
            "The UC-MSC treatment group one subject was not included in the analysis due to death, one subject was not included due to discharge on day 6. In the control group one subject was not included in the analysis due to death before day 6.",
            "One subject in the control group died before day 3 post first infusion.",
            "In the UC-MSC group one patient was censored and died before day 6 and one patient recovered before day 6 and left the hospital. In the control group on patient died before day 6 post first infusion.",
            "In the UC-MSC group one patient was censored and died before day 6, 6 patients left the hospital before day 6 post first infusion. In the control group 4 patients died, 3 patients left the hospital and one left hospital against medical advice before day 6 post first infusion.",
            "These analyses were implemented in a protocol version that did not apply to 2 patients of the UC-MSC treatment group and 3 patients of the control group. In the UC-MSC group one patient was censored and died before day 6, 4 patients left the hospital before day 6 post first infusion and in one patient blood was not drawn. In the control group 3 patients died, 3 patients left the hospital and one left hospital against medical advice before day 6 post first infusion."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "6 and 24 hours",
            "31 days",
            "90 days",
            "90 days",
            "90 days",
            "90 days",
            "90 days",
            "90 days",
            "31 Days",
            "60 days",
            "31 days",
            "28 days post second infusion",
            "90 days or hospital discharge, whichever is earlier",
            "day 6",
            "day 6",
            "day 6",
            "Day 6",
            "90 days",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "Day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 3 post first infusion",
            "day 6",
            "day 14",
            "day 14 post first infusion"
      ],
      "OutcomeMeasureTitle": [
            "Number of Participants With Pre-Specified Infusion Associated Adverse Events",
            "Number of Subjects With Serious Adverse Events by 31 Days After First Infusion",
            "Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90",
            "Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)",
            "Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity",
            "Subjects With Adverse Events and Serious Adverse Events by Severity",
            "Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment",
            "Subjects With Adverse Events by Relatedness to Treatment",
            "Survival at 31 Days Post First Infusion",
            "Survival at 60 Days Post First Infusion",
            "Time to Recovery",
            "Ventilator-Free Days Throughout 28 Days Post Second Infusion",
            "Ventilator-Free Days Throughout 90 Days",
            "Respiratory Rate and Oxygenation Index (ROX Index)",
            "Oxygenation Index (OI)",
            "Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)",
            "Sequential Organ Failure Assessment (SOFA) Scores",
            "Smell Identification Test (SIT) Scores",
            "White Blood Cell Count (WBC)",
            "Platelets Count",
            "Hemogoblin",
            "Hematocrit",
            "Neutrophils",
            "Lymphocytes",
            "Glomerular Filtration Rate",
            "Total Protein",
            "Sodium",
            "Potassium",
            "Creatinine",
            "Glucose",
            "Albumin",
            "Alkaline Phosphatase",
            "Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)",
            "Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)",
            "Total Bilirubin",
            "Blood Urea Nitrogen (BUN)",
            "Calcium",
            "Chloride",
            "Carbon Dioxide (CO2)",
            "C-Reactive Protein Levels",
            "Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio",
            "D-dimer Levels",
            "25-Hydroxy Vitamin D Levels",
            "Tumor Necrosis Factor-alpha (TNF\u03b1)",
            "Tumor Necrosis Factor-beta (TNF\u03b2)",
            "Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)",
            "Viral Load by SARS-CoV-2 RT-PCR",
            "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion",
            "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion",
            "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion",
            "Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "Participants",
            "Participants",
            "percentage of participants",
            "Adverse Events",
            "Adverse Events",
            "Participants",
            "Adverse Events",
            "Participants",
            "Participants",
            "Participants",
            "days",
            "days",
            "days",
            "Index",
            "Index",
            "cm H2O",
            "score on a scale",
            "10^3 cells/uL",
            "10^3 cells/uL",
            "g/dL",
            "percentage of red blood cells by volume",
            "10^3 cells/uL",
            "10^3 cells/uL",
            "mL/min/1.73 m^2",
            "g/dL",
            "mmol/L",
            "mmol/L",
            "mg/dL",
            "mg/dL",
            "g/dL",
            "U/L",
            "U/L",
            "U/L",
            "mg/dL",
            "mg/dL",
            "mg/dL",
            "mmol/L",
            "mmol/L",
            "mg/L",
            "ratio of AA to EPA",
            "mcg/ml FEU",
            "ng/ml",
            "pg/mL",
            "pg/mL",
            "pg/mL",
            "RNA copies/mL",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeMeasurementComment": [
            "insufficient number of people recovered within 31 day limit to estimate the upper confidence",
            "insufficient number of people recovered within 31 day limit",
            "insufficient number of people recovered within 31 day limit",
            "insufficient number of people recovered within 31 day limit to estimate the upper confidence"
      ],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeMeasurementLowerLimit": [
            "13.00",
            "NA",
            "6",
            "10",
            "3",
            "9",
            "24",
            "0",
            "86",
            "0",
            "228",
            "368",
            "494",
            "852",
            "0",
            "0"
      ],
      "OutcomeMeasurementSpread": [
            "5.23",
            "2.9",
            "1.43",
            "5.21",
            "3.72",
            "1.53",
            "9.61",
            "2.83",
            "2.7",
            "2.36",
            "4.62",
            "5.6",
            "136.33",
            "135.59",
            "2.82",
            "3.34",
            "8.32",
            "9.56",
            "4.27",
            "5.95",
            "1.07",
            "0.41",
            "26.99",
            "35.4",
            "0.54",
            "1.06",
            "6.24",
            "9.57",
            "0.71",
            "0.73",
            "0.54",
            "0.74",
            "63.99",
            "82.33",
            "0.43",
            "0.45",
            "68.36",
            "219.13",
            "38.43",
            "45.04",
            "23.86",
            "32.47",
            "0.46",
            "0.29",
            "22.28",
            "26.97",
            "0.58",
            "0.67",
            "7.63",
            "9.04",
            "3.75",
            "4.61",
            "131.05",
            "104.7",
            "12",
            "13.24",
            "11.29",
            "3.38",
            "8.91",
            "16.38",
            "3071.96",
            "3086.03"
      ],
      "OutcomeMeasurementUpperLimit": [
            "NA",
            "NA",
            "23",
            "NA",
            "15",
            "NA",
            "28",
            "28",
            "90",
            "90",
            "407",
            "1730",
            "1260",
            "5890",
            "0",
            "2193"
      ],
      "OutcomeMeasurementValue": [
            "1",
            "1",
            "1",
            "1",
            "0",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "2",
            "8",
            "41.67",
            "66.67",
            "40",
            "37",
            "6",
            "16",
            "15",
            "13",
            "22",
            "21",
            "9",
            "19",
            "7",
            "5",
            "7",
            "8",
            "5",
            "7",
            "42",
            "45",
            "3",
            "7",
            "1",
            "1",
            "0",
            "0",
            "0",
            "0",
            "8",
            "10",
            "1",
            "4",
            "1",
            "1",
            "0",
            "0",
            "0",
            "0",
            "10",
            "5",
            "9",
            "5",
            "23",
            "NA",
            "15",
            "NA",
            "8",
            "12",
            "28",
            "0",
            "90",
            "0",
            "9.57",
            "7.44",
            "9.62",
            "12.74",
            "9.73",
            "11.67",
            "28.67",
            "24",
            "6.56",
            "6.82",
            "13.43",
            "15.53",
            "342",
            "397.89",
            "11.93",
            "11.94",
            "37.98",
            "36.73",
            "9.74",
            "13.4",
            "1.38",
            "0.8",
            "60.59",
            "68.67",
            "5.88",
            "5.8",
            "141.22",
            "141",
            "4.25",
            "4.37",
            "1.21",
            "1.24",
            "153.11",
            "183.89",
            "2.96",
            "2.73",
            "136.2",
            "202.5",
            "64.4",
            "65.67",
            "55.8",
            "47",
            "0.88",
            "0.77",
            "48",
            "47.67",
            "8.5",
            "8.27",
            "101.56",
            "102.44",
            "28.44",
            "26.44",
            "101.01",
            "112.55",
            "33.6",
            "34.64",
            "6.2",
            "4.69",
            "23.21",
            "27.58",
            "349",
            "451",
            "829",
            "1540",
            "26609.09",
            "23111.11",
            "0",
            "0",
            "10",
            "11",
            "2",
            "0",
            "4",
            "6",
            "8",
            "5",
            "9",
            "9",
            "1",
            "2",
            "5",
            "5",
            "5",
            "6",
            "5",
            "3",
            "0",
            "1",
            "4",
            "2",
            "1",
            "2",
            "2",
            "2",
            "1",
            "0",
            "1",
            "0",
            "4",
            "2",
            "0",
            "0",
            "0",
            "0"
      ],
      "OverallOfficialAffiliation": [
            "University of Miami"
      ],
      "OverallOfficialName": [
            "Camillo Ricordi, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "ricordi@miami.edu"
      ],
      "PointOfContactOrganization": [
            "University of Miami"
      ],
      "PointOfContactPhone": [
            "305-243-6913"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Camillo Ricordi"
      ],
      "PrimaryCompletionDate": [
            "October 31, 2020"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Safety as defined by the number of pre-specified infusion associated adverse events as assessed by treating physician. Any of the following occurring within 6 h post each infusion:\n\nAn increase in vasopressor dose greater than or equal to the following:\n\nNorepinephrine: 10 \u03bcg/min\nPhenylephrine: 100 \u03bcg/min\nDopamine: 10 \u03bcg/kg/min\nEpinephrine: 10 \u03bcg/min\nIn patients receiving mechanical ventilation: worsening hypoxemia, as assessed by a requirement for an increase of PEEP by 5 cm H2O over baseline, or requirement to increase FiO2 of >20%.\nIn patients receiving high flow oxygen therapy: worsening hypoxemia, as indicated by requirement of intubation and mechanical ventilation.\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fibrillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24h post infusion",
            "The number of subjects experiencing serious adverse events by 31 days after the first infusion (corresponding to 28 days after the last infusion).",
            "Safety will be reported as the percentage of participants experiencing serious adverse events through Day 90 as assessed by treating physician.",
            "Total number of adverse events and serious adverse events as assessed by treating physician",
            "Total number of adverse events plus serious adverse events categorized by severity.",
            "Total number of subjects with adverse events and serious adverse events categorized by severity.",
            "Total number of adverse events and serious adverse events categorized by relatedness to treatment defined by a medical professional.",
            "Total number of subjects with adverse events categorized by relatedness to treatment by a medical professional"
      ],
      "PrimaryOutcomeMeasure": [
            "Number of Participants With Pre-Specified Infusion Associated Adverse Events",
            "Number of Subjects With Serious Adverse Events by 31 Days After First Infusion",
            "Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90",
            "Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)",
            "Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity",
            "Subjects With Adverse Events and Serious Adverse Events by Severity",
            "Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment",
            "Subjects With Adverse Events by Relatedness to Treatment"
      ],
      "PrimaryOutcomeTimeFrame": [
            "6 and 24 hours",
            "31 days",
            "90 days",
            "90 days",
            "90 days",
            "90 days",
            "90 days",
            "90 days"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of Miami"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Camillo Ricordi"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Professor of Surgery and Chief, Division of Cellular Transplantation"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [
            "December 6, 2021"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [
            "October 25, 2021"
      ],
      "ResultsFirstPostedQCCommentsDateType": [
            "Actual"
      ],
      "ResultsFirstSubmitDate": [
            "October 15, 2021"
      ],
      "ResultsFirstSubmitQCDate": [
            "December 1, 2021"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "20200370"
      ],
      "SecondaryIdDomain": [
            "Secondary Protocol ID"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Other Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "Number of participants that are alive at 31 days post first infusion follow up corresponding to 28 day post second infusion.",
            "Number of participants alive at 60 days post first infusion follow up.",
            "Time to discharge or, if the subject was hospitalized, no longer requiring supplemental oxygen and no longer requiring COVID-19-related medical care by 31 days. The numbers represent days at which 25%, 50%, 75% subjects within the treatment group had recovered.",
            "Number of days participants were off ventilators during 28 days post second infusion.",
            "Number of days participants were off ventilators within up to 90 days of hospitalization.",
            "Respiratory Rate-Oxygenation (ROX) index is defined as the ratio of oxygen saturation as measured by pulse oximetry (SpO2)/ Fraction of inspired oxygen (FiO2) to respiratory rate. This index can be used in the assessment of disease progression and the risk of intubation in COVID-19 patients with pneumonia.",
            "Measure of the fraction of inspired oxygen (FiO2) and its usage within the body during intensive care, measured using fNIRS (Functional Near Infrared Spectroscopy). The calculation for Oxygenation index is ((FIO2 * Mean airway pressure)/partial pressure of oxygen).",
            "Measuring the respiratory mechanics; positive end-expiratory pressure (PEEP) and plateau pressure (Pplat) in ventilated patients visit 8 (day 6)",
            "Sequential Organ Failure Assessment (SOFA) Scores is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from a minimum of 0 (normal) to a maximum of 4 (high degree of dysfunction/failure). The total score corresponds to the sum of the six different scores of the organ systems. In total, the minimum SOFA score is 0 (normal) and the maximum SOFA score is 24 (highest degree dysfunction/failure).",
            "SIT measures the participant's sense of smell. SIT has a total score ranging from 0 to 40 with the higher the score indicating a more normal sense of smell",
            "As assessed via serum blood samples.",
            "As assessed via serum blood samples.",
            "Measures the total amount of the oxygen-carrying protein in the blood as assessed via serum blood samples.",
            "The percentage by volume of red cells in your blood as assessed via serum blood samples.",
            "the amount of immune cells (that is one of the first cell types to travel to the site of an infection) as assessed via serum blood samples",
            "Lymphocyte count as assessed via serum blood samples",
            "Glomerular filtration rate (GFR) as assessed via serum blood samples to check how well the kidneys are working. It estimates how much blood passes through the glomeruli each minute.",
            "Total protein as assessed via serum blood samples as a part of the comprehensive metabolic panel (CMP). It is a measurement of the sum of albumin and globulins.",
            "Sodium levels as assessed by serum blood samples.",
            "Potassium levels as assessed via serum blood samples.",
            "Creatinine levels as assessed via serum blood samples",
            "Glucose levels as assessed via serum blood samples",
            "Albumin levels as assessed via serum blood samples",
            "Alkaline phosphatase levels as assessed via serum blood samples for the Comprehensive Metabolic Panel.",
            "The alanine aminotransferase or serum glutamate-pyruvate transaminase (ALT or SGPT) test as assessed via serum blood samples",
            "The aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST or SGOT) test as assessed via serum blood samples",
            "Bilirubin levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Blood urea nitrogen (BUN) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Calcium levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Chloride levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "Carbon Dioxide (CO2) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
            "As assessed via serum blood samples.",
            "As assessed via serum blood samples on day 6 (visit 8).",
            "As assessed via serum blood samples.",
            "As assessed via serum blood samples.",
            "Analysis of TNF\u03b1 in peripheral blood plasma",
            "Analysis of TNF\u03b2 in peripheral blood plasma",
            "Analysis of soluble tumor necrosis factor receptor 2 (sTNFR2) in peripheral blood plasma",
            "Viral load as assessed in blood plasma for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) via Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).",
            "Number of participants reporting panel reactive antibody (PRA) positivity at Day 3 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
            "Number of participants reporting panel reactive antibody (PRA) positivity at Day 6 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
            "Number of participants reporting panel reactive antibody (PRA) positivity at Day 14 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
            "Number of participants with positive, negative, or borderline SARS-CoV-2 Immunoglobulin M (IgM)/Immunoglobulin G (IgG) serology from serum blood samples."
      ],
      "SecondaryOutcomeMeasure": [
            "Survival at 31 Days Post First Infusion",
            "Survival at 60 Days Post First Infusion",
            "Time to Recovery",
            "Ventilator-Free Days Throughout 28 Days Post Second Infusion",
            "Ventilator-Free Days Throughout 90 Days",
            "Respiratory Rate and Oxygenation Index (ROX Index)",
            "Oxygenation Index (OI)",
            "Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)",
            "Sequential Organ Failure Assessment (SOFA) Scores",
            "Smell Identification Test (SIT) Scores",
            "White Blood Cell Count (WBC)",
            "Platelets Count",
            "Hemogoblin",
            "Hematocrit",
            "Neutrophils",
            "Lymphocytes",
            "Glomerular Filtration Rate",
            "Total Protein",
            "Sodium",
            "Potassium",
            "Creatinine",
            "Glucose",
            "Albumin",
            "Alkaline Phosphatase",
            "Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)",
            "Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)",
            "Total Bilirubin",
            "Blood Urea Nitrogen (BUN)",
            "Calcium",
            "Chloride",
            "Carbon Dioxide (CO2)",
            "C-Reactive Protein Levels",
            "Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio",
            "D-dimer Levels",
            "25-Hydroxy Vitamin D Levels",
            "Tumor Necrosis Factor-alpha (TNF\u03b1)",
            "Tumor Necrosis Factor-beta (TNF\u03b2)",
            "Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)",
            "Viral Load by SARS-CoV-2 RT-PCR",
            "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion",
            "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion",
            "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion",
            "Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG"
      ],
      "SecondaryOutcomeTimeFrame": [
            "31 Days",
            "60 days",
            "31 days",
            "28 days post second infusion",
            "90 days or hospital discharge, whichever is earlier",
            "day 6",
            "day 6",
            "day 6",
            "Day 6",
            "90 days",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "Day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 6",
            "day 3 post first infusion",
            "day 6",
            "day 14",
            "day 14 post first infusion"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Cardiac disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Cardiac disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Psychiatric disorders",
            "Cardiac disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "General disorders",
            "Cardiac disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Infections and infestations"
      ],
      "SeriousEventSourceVocabulary": [
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0",
            "CTCAE Version 5.0"
      ],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "3",
            "0",
            "1",
            "0",
            "1",
            "0",
            "2",
            "1",
            "4",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1"
      ],
      "SeriousEventStatsNumAtRisk": [
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12",
            "12"
      ],
      "SeriousEventStatsNumEvents": [
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "3",
            "0",
            "1",
            "0",
            "1",
            "0",
            "2",
            "1",
            "4",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1"
      ],
      "SeriousEventTerm": [
            "GI Bleeding 2ry to Clostridium Difficile Infection",
            "Colon Perforation",
            "Cardiact Arrest-Death due to Difficult Intubation",
            "Acute respiratory Failure 2ry to COVID-Death",
            "Atrial Flutter",
            "Death-Acute Hypoxemic Respiratory Failure Secondary to COVID-19 Pneumonitis",
            "Psychosis",
            "Cardiac Arrest/Pulseless Electrical Activity Cardiac Arrest/Cardiac Arrest Secondary to Acute Respir",
            "Traumatic Tension Pneumotorax post-CPR",
            "Severe Respiratory Acidosis",
            "[DEATH] Multisystem Organ Failure (Death)/Multiple Organ Dysfunction Syndrome-Death",
            "[DEATH] Cardiac Arrest-Death/Cardiopulmonary Arrest-Death/Asystole -Death",
            "Hyperkalemia",
            "Severe Metabolic Acidosis",
            "Septic Shock-Hospital acquired Pseudomona Aeruginosa bacteremia"
      ],
      "StartDate": [
            "April 25, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "December 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 21, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "April 13, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "April 17, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}